• Study Shows That Caris Life Sciences’ ADAPT Biotargeting System™ Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer Patient Subpopulations

    First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery   IRVING, Texas, Feb. 12, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting System™ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, … Read More

  • Caris Life Sciences Appoints New Executive Medical Director

    IRVING, Texas, Feb. 11, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today Matthew Oberley, M.D., Ph.D., has been appointed Executive Medical Director.   Dr. Oberley joined Caris in August 2019 as Senior Medical Director and has functioned as a leading face for Caris’ clinical and scientific expertise in the marketplace and research community. His responsibilities have included managing the Company’s Medical Science Liaison team and helping connect key oncology research leaders across the country with the large datasets Caris has generated through the Company’s molecular profiling technology. … Read More

  • Cedars-Sinai Joins Caris Life Sciences’ Precision Oncology Alliance

    Nationally recognized center becomes 33rd member of Caris’ collaborative network focused on expanding the application of precision medicine in cancer treatment   IRVING, Texas & LOS ANGELES, Calif., Jan. 14, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that the Samuel Oschin Comprehensive Cancer Institute at Los Angeles-based Cedars-Sinai has become the 33rd member of its Precision Oncology Alliance™. … Read More

  • Caris Life Sciences Adds Premier Academic Brain Tumor Center to its Precision Oncology Alliance

    The NCI-designated Institute becomes 32nd member of Caris’ collaborative network focused on expanding the application of precision medicine in cancer treatment   IRVING, Texas & DURHAM, N.C., Jan. 14, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that The Preston Robert Tisch Brain Tumor Center at Duke University Hospital has become the 32nd member of its Precision Oncology Alliance™. … Read More

  • Caris Life Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    IRVING, Texas, Jan. 2, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020, at 11:00 a.m. Pacific Time at the Westin St. Francis Hotel, Elizabethan C room, in San Francisco.  The company will provide an overview of the business and discuss recent corporate achievements that position it to further extend its leadership in the market. … Read More